Sorin Brener, MD
Interventional Cardiology · Brooklyn, NYNPI 1104930338
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 68.6% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $47,563 and has fallen 72.9% since, to $12,875 in 2025. Among interventional cardiology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 239 payments — averaging $695.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$114K
- Abbott$43K
- Medtronic$6K
- Contego Medical, Inc$2K
- Boston Scientific$542
- Abiomed$440
- plus $984 from 9 others
Across 5 payments — averaging $1100.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$6K
Across 7 payments — averaging $1189.29 each. An ownership or investment interest held by the physician or an immediate family member.
- Contego Medical, Inc$8K
What the payments were for
- Consulting fees$40,81625%
- Speaking & faculty fees$98,25059%
- Travel & lodging$16,89410%
- Food & beverage$10,2616%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 107 | $114,044 |
| Abbott | 80 | $42,544 |
| Medtronic(2 entities) | 22 | $5,686 |
| Contego Medical, Inc | 1 | $2,000 |
| Boston Scientific | 8 | $542 |
| Abiomed | 7 | $440 |
| Edwards Lifesciences | 4 | $404 |
| Siemens Medical Solutions USA, Inc. | 2 | $168 |
| Biotronik Inc. | 1 | $124 |
| Terumo Medical Corporation | 1 | $123 |
| Novartis | 2 | $54 |
| Irhythm Technologies, Inc. | 1 | $44 |
| Amgen | 1 | $24 |
| Chiesi USA, Inc. | 1 | $22 |
| Baxter Healthcare | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRILINTA$95,538
- XIENCE V$23,000
- FARXIGA$17,616
- XIENCE SKYPOINT$12,875
- CoreValve Evolut$5,256
- DRAGONFLY OPSTAR$1,711
- MitraClip$1,073
- XIENCE XPEDITION$1,000
- Tricuspid Valve Repair System$500
- Impella$371
- PRESSUREWIRE$296
- STINGRAY$260
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$184
- SAPIEN 3 Ultra RESILIA$158
- XIENCE SIERRA$131
- Dragonfly OCT$131
- Orsiro Mission$124
- ANGIO-SEAL$123
- AVVIGO Guidance System$116
- Artis icono floor$113
How this compares
$166,239 in reported general payments places this provider in the 90th percentile of 382 interventional cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 45 | $54,854 |
| EliquisApixaban | 17 | $25,177 |
| Metoprolol Succinate | 45 | $1,038 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 11 | $480 |
| Atorvastatin Calcium | 40 | $473 |
| ClopidogrelClopidogrel Bisulfate | 44 | $466 |
| Pantoprazole Sodium | 17 | $374 |
| Furosemide | 20 | $244 |
| Lisinopril | 35 | $219 |
| Amlodipine Besylate | 21 | $111 |
| Carvedilol | 13 | $98 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $54 | $54,85445 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 382 interventional cardiology providers in New York.
Other interventional cardiology in Brooklyn
- Peter RouvelasBrooklyn$332K
- Justin RatcliffeBrooklyn$137K
- Robert FrankelBrooklyn$59K
- Sahil ParikhNew York$1.6M
- Deepak BhattNew York$1.6M
- Martin LeonNew York$1.5M
- Evan ShlofmitzRoslyn$951K
- Mohamed Azeem LatibBronx$816K
- Yili HuangElmhurst$699K
- Ali HaiderAstoria$492K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.